This unexpected finding may reflect disease-specific immune dysregulation or differences in treatment regimens, as RA patients in our study were less likely to have received anti-TNF-α agents compared to those with psoriasis (59.5% overall, with adalimumab predominant). This evidence concerns the gene TNF and rheumatoid arthritis.